Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

New treatment platform delivers full-length mRNA for Duchenne muscular dystrophy

11

Jun 2026

New treatment platform delivers full-length mRNA for Duchenne muscular dystrophy

A new treatment platform developed by researchers at The University of Texas MD Anderson Cancer Center was able to deliver messenger RNA (mRNA) of the full-length DMD gene into preclinical models of Duchenne muscular dystrophy, successfully restoring the production of an important muscle protein, dystrophin, and dramatically improving muscle strength, endurance and function in vivo.

Teenage risk-taking linked to lower baseline dopamine levels

11

Jun 2026

Teenage risk-taking linked to lower baseline dopamine levels

Teenage risk-taking, such as experimentation with alcohol, cannabis, nicotine and other substances, may reflect a compensatory response to lower baseline dopamine, the brain chemical for reward activity, suggests a new University of Pittsburgh School of Medicine study, published today in Nature Communications.

Chronic pancreatitis care must expand beyond simple pain management

11

Jun 2026

Chronic pancreatitis care must expand beyond simple pain management

Chronic pancreatitis (CP) diminishes quality-of-life (QoL) across mobility, self-care, daily activities, mental health, and pain-not just abdominal discomfort-according to a new Mayo Clinic study available online on August 27, 2025, and published in Volume 9, Issue 1 of the Journal of Pancreatology on March 30, 2026.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.